— Main Menu —
HOME
DCVAX ® TECHNOLOGY
- About DCVax®
- Dendritic Cell Immunotherapy
- Patient Stories & Physician Comments
PRODUCT CANDIDATES
- DCVax® – L
- DCVax® – Direct
- DCVax® – Prostate
CLINICAL TRIALS
- Pipeline
- DCVax® – L Phase III for GBM Brain Cancer
- DCVax® – Direct Phase I/II for All Types of Inoperable Solid Tumor Cancers
INVESTORS & MEDIA
- Press Releases
- SEC Filings
- Webcasts
- Board Committee Charters
- Code of Conduct
- Notice of Proposed Settlement
- Related-Party Transaction Policy
- Corporate Governance Guidelines
ABOUT US
- Overview
- Company Management
- Publications
- Related Links
- Contact Us
HOME
DCVAX ® TECHNOLOGY
About DCVax®
Dendritic Cell Immunotherapy
Patient Stories & Physician Comments
PRODUCT CANDIDATES
DCVax® – L
DCVax® – Direct
DCVax® – Prostate
CLINICAL TRIALS
Pipeline
DCVax® – L Phase III for GBM Brain Cancer
DCVax® – Direct Phase I/II for All Types of Inoperable Solid Tumor Cancers
INVESTORS & MEDIA
Press Releases
SEC Filings
Webcasts
Board Committee Charters
Code of Conduct
Notice of Proposed Settlement
Related-Party Transaction Policy
Corporate Governance Guidelines
ABOUT US
Overview
Company Management
Publications
Related Links
Contact Us
var lsjQuery = jQuery;
> Our Technology
DCVax® is a platform
> Our Products
Northwest Biotherapeutics, Inc
 is a clinical stage biotechnology company focused on the development of personalized cancer vaccines designed to treat a broad range of solid tumor cancers.

Read more about NW Bio >>
DCVax-L Patients From UCLA
UCLA Department of Neurosurgery

Dr. Linda Liau discusses our DCVax-L clinical trial for glioblastoma brain cancer and describes the positive impact it has had on patients. Brad and Jennifer share their stories about diagnosis and their choice to receive DCVax.
Most Recent Presentations
29
AUG
2018
Dr. Marnix Bosch’s Presentation on Clinical Development of Dendritic Cell-Based Immunotherapy for Cancer at Immuno-Oncology Summit
Download the Presentation.
View article in 
Clinical Cancer Research
.
07
JUN
2018
Webcast: Dr. Marnix Bosch’s Presentation on DCVax® Personalized Dendritic Cell Vaccines from ASCO 2018
View the recorded webcast
.
Press Releases
19
NOV
2018
Updated Interim Data from Phase 3 Trial of DCVax®-L for Glioblastoma
13
NOV
2018
NW Bio Announces $5 Million Bridge Funding
28
AUG
2018
NW Bio Announces Upcoming Presentation By Dr. Marnix Bosch At Immuno-Oncology Summit
Proxy Statement
09
JAN
2018
Annual Meeting Proxy Statement
DCVAX® TECHNOLOGY
About DCVax®
Dendritic Cell Immunotherapy
Patient Stories & Physician Comments
PRODUCT CANDIDATES
DCVax® – L
DCVax® – Direct
DCVax® – Prostate
CLINICAL TRIALS
Pipeline
DCVax® – L Phase III
DCVax® – Direct Phase I/II
INVESTORS & MEDIA
Contacts
SEC Filings
Stock Information
Press Releases
Webcasts
ABOUT US
Overview
Company Management
Publications
Related Links
Contact Us
© 2017 Northwest Biotherapeutics, Inc.
Forward-looking Statement
Legal Disclaimer
Privacy Policy